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The role that bone marrow microenvironment plays in differentiation, migration, proliferation, survival and drug 
resistance of malignant plasma cells has attracted significant attention in the attempt to identify new druggable 
targets in multiple myeloma (MM).
1
  
Heparanase is an endo-ß-d-glucuronidase that trims the heparan sulfate (HS) chains of proteoglycans, impacting cell 
signaling, gene expression and promoting extracellular matrix (ECM) remodeling within the tumor 
microenvironment.
2-4
 
Heparanase is highly upregulated in the great majority of MM patients and associated with elevated micro vessel 
density and enhanced shedding of the HS proteoglycan syndecan-1
5
, events that are highly relevant to disease 
progression.
6, 7
 
In preclinical models of MM, heparanase was shown to be a master regulator of aggressive tumor behavior and 
bortezomib or melphalan were found to enhance heparanase expression and secretion.
 
High heparanase expressing 
MM cells are less susceptible to cytotoxic effects of bortezomib or melphalan.
8-10
 
Roneparstat (laboratory codes: G4000, SST0001; Leadiant Biosciences, formerly sigma tau Research Switzerland SA) is 
a chemically modified 100% N-desulphated, N-reacetylated and 25% glycol-split heparin with very low anticoagulant 
activity and a molecular weight between 15.000 and 25.000 Da. It is a very potent and pure competitive HPSE 
inhibitor.
11, 12
 
Roneparstat showed a significant anti-myeloma effect in murine models, either alone or in combination with 
dexamethasone, bortezomib or melphalan.
10,13
 
Based on this preclinical evidence an open-label, multicenter, phase I first-in-human study was designed to assess the 
safety and tolerability profile of Roneparstat in patients with relapsed/refractory MM. (EudraCT number 2012-
001127-12 and clinicaltrials.gov identifier: NCT01764880). 
Patients with advanced relapsed/refractory MM were eligible to be enrolled. Two treatment schedules were used: 
every day for 5 days (schedule A) and every day for 5 days week 1 and week 2 (schedule B), in a cycle of 28 days, 
according to a 3+3 design (see Table 1); Roneparstat was administered subcutaneously.  
Dose Limiting Toxicities (DLTs) were characterized as per National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE) version 4.0. Safety assessment of the drug was based on adverse events (AE), local 
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tolerability evaluation, physical examination, vital signs and laboratory tests. Patients could receive a standard 
supportive therapy with dexamethasone. Use and doses of dexamethasone were upon physician’s judgment. 
Blood samples were collected during cycle 1, on Day 1 over 24 h, and on the last day of treatment (Day 5 or Day 12) 
over 72 h. Pharmacokinetic (PK) sampling was performed during the first cycle. Plasma samples were analysed by a 
fluorescent probe assay (Heparin Red).
14
  
The anti-MM activity assessment was based on a surrogate parameter, the monoclonal protein modifications in serum 
and urine, evaluated accordingly to IMWG (International Myeloma Working Group) Guidelines.
 
Nineteen patients with advanced relapsed/refractory MM were enrolled into the study and completed a total of 57 
cycles (514 doses), with a median of 2 cycles (range 1-11). Four patients received > 5 cycles. Baseline patients’ 
characteristics and enrolment by cohort of treatment are reported in Table 1.  
Roneparstat was well tolerated and safe at all doses tested.  
Seventeen patients reported a total of 88 AEs. Most common AEs in at least 10% of patients are reported in Table 2. 
Most of the AEs were grade 1 or 2 and unrelated, except for 3 treatment-related AEs in three patients (viral infection, 
injection site reaction, abdominal pain), assessed as Grade 1/2, transient and recovered with conservative therapy.  
Grade 3/4 AEs included general physical health deterioration (3 patients, 15.8%), anemia, thrombocytopenia and 
bone pain (2 patients each, 10.5%); neutropenia, gastric hemorrhage, and hyperglycemia (1 patient each, 5.3%). None 
of these events were assessed by the investigators as related to study treatment. 
Five patients experienced 6 serious adverse events (SAEs), only one (viral infection) was assessed as related to study 
drug, although correlation with the concomitant treatment with dexamethasone could not be excluded. The 
remaining SAEs were unrelated: general physical health deterioration in 2 patients, pneumonia in one patient, a 
suspected gastrointestinal hemorrhage in one patient (that the endoscopic evaluation did not confirm) and gastric 
hemorrhage in one patient (the patient was enrolled with a gastric myeloma lesion and presented progressive disease 
while on Roneparstat therapy). SAEs were transient, patients recovered with conventional therapy except one general 
physical health deterioration, ongoing at end of study.  
No patients succumbed due to toxicity of the study drug. Nine patients died during the study, all from tumor 
progression. 
Fifteen patients reported 31 local reactions at the injection site. Local side effects were < Grade 2, transient and 
resolved with conventional therapy, when needed. Only one was Grade 2 (redness).   
Due to Roneparstat similarity with heparin, the risk of bleeding was carefully monitored. TT and INR indicated that 
there was no evident relationship with Roneparstat administration following single or repeated dosing. For aPTT there 
was no association with dose upon single dosing; after repeated dosing aPTT pharmacodynamic parameters (Emax 
and AUEC0-t) were higher at 200 and 400 mg/day than at lower doses, without reaching clinically meaningful levels. 
The coagulation results by worst CTCAE Grade did show one Grade 1 in one patient (5.3%) for aPTT and one grade 1 
and one grade 2 in 1 (5.3%) and 4 patients (21.1%), respectively, for INR. 
In the 17 patients evaluable for DLTs, no clinically relevant toxicities occurred and no DLTs were observed, a true MTD 
was not reached. Dose escalation was stopped based on safety and PK data, indicating patients could be exposed to 
the study drug at dose levels of 200 and 400 mg/day without any clinically relevant toxicities.  
Reproducible plasma levels of Roneparstat were measurable at cycle 1 at the two highest dose levels, as shown in 
Supplementum Figure S1 depicting single patient plasma concentration at day 1 and day 12 (single and repeat dosing, 
respectively). There was a dose-related increase in mean Cmax between 200 mg/day and 400 mg/day, both on day 1 
(1.67 µg/mL vs 2.45 µg/mL) and day 12 (2.07 µg/mL vs 5.95 µg/mL). The mean exposure (AUC0-t) at day 1 after 
repeated dosing was 16.2 µg.h/mL and 37.25 µg.h/mL, while at day 12 it was 15.4 µg.h/mL and 133µg.h/mL for 200 
mg and 400 mg/day, respectively. Upon repeated dosing, tmax was achieved at approximately 3-hour post-dose. On 
Day 12 and at 400 mg/day, the estimated T1/2 was approximately 14-20 h (2 patients).  
Seventeen patients that received at least 1 cycle of Roneparstat were evaluable for overall response assessment 
(Table 3). One PR (5.9%) and 9 SD (52.9%) were observed. The remaining patients (41.2%) presented PD. The PR 
occurred in a patient receiving Roneparstat 50 mg, who relapsed after 3 prior therapy lines with a continuous increase 
of the monoclonal component. Response was characterized by a rapid decrease of the monoclonal component, from 
1.75 g/dL at baseline to 0.99 g/dL at cycle 1, 0.71 g/dL at cycle 6. The patient remained on therapy until cycle 9 with 
sustained clinical benefit. Two of the 9 SDs were sustained with significant clinical benefit (10 and 7 months) following 
200 mg and 400 mg of Roneparstat. The PR and one prolonged SD patients received low dose of concomitant 
dexamethasone (up to 40 mg/week), while the other prolonged SD did not receive any dexamethasone. 
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This is the first trial evaluating an heparanase inhibitor in hematological malignancies. Heparanase represents an 
increasingly studied but still largely unexploited target for anticancer therapy. Our data show that Roneparstat 
presents an excellent safety profile, without clinically relevant systemic reactions, and an excellent tolerability profile. 
Systemic exposure appears measurable in a reproducible and linear fashion at 200 and 400 mg. This study allowed 
identification of doses within the range from 300 to 400 mg/day as suitable for further development of the drug. 
Roneparstat showed little efficacy in this specific experimental setting. Heparanase inhibition is not expected to yield 
tumor cell kill directly and evidence of efficacy was beyond the main scope of this trial also given the advanced heavily 
treated patient population, the trial size, and the design allowing a concomitant administration of dexamethasone. 
However, the safe and well tolerated profile of Roneparstat that can be learnt from this clinical experience combined 
with the extensive preclinical evidence on the ability of heparanase inhibition to influence the bone marrow 
microenvironment in myeloma patients, and the synergistic effect of Roneparstat when associated with bortezomib 
or melphalan suggest the possibility to capitalize and improve the role of heparanase inhibition in myeloma treatment. 
In fact, the involvement of heparanase in regulating the cross talking between the tumor and the host myeloma 
microenvironment and Roneparstat preclinical activity in combination regimens
8-10 
have been widely described (see 
Supplementum 1). Of particular interest, Ramani et al
10 
reported a very significant effect on tumor burden when 
Roneparstat was combined with bortezomib or melphalan to treat mice bearing an aggressive myeloma in vivo model 
formed by CAG human myeloma cells expressing high levels of heparanase (CAG-HPSE cells). Therefore, even though 
this phase I study does not provide evidence on the potential direct anti-myeloma effect of Ronepartstat in humans, 
exploration of Roneparstat in combination regimens for the treatment of MM is justified and should be the next step 
to move the field. 
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Tables  
 
Table 1  
Baseline patients’ characteristics, patient enrolment by cohort of treatment  
and cycles administered. 
 
 No. of  
patients  
No. of  
cycles 
Age, years, median (range):  68 (51-81)   
Male/Female 
8 / 11 
 
SCHEDULE A: every day for 5 days, 
week 1 
                               Dose 1
st
 cohort: 25 mg 
 
SCHEDULE B: every day for 5 days,  
week 1 and week 2 
                               Dose 2
nd
  cohort: 25 mg 
                               Dose 3
rd
  cohort:  50 mg 
                               Dose 4
th
  cohort: 100 mg 
                               Dose 5
th
  cohort: 200 mg 
                               Dose 6
th
  cohort: 400 mg 
 
 
4* 
 
 
 
3 
2** 
3  
3 
4* 
 
 
6 
 
 
 
 8 
11 
 4 
15 
13 
Salmon & Durie staging                                I 
                                                                          II 
                                                                         III 
International Staging System                      I 
                                                                          II  
                                                                         III 
1 
2  
16  
 
13  
4  
2  
 
No prior lines, median, range:  4 (1-8)  
Prior PI/IM/RT 
 
PI = proteasome inhibitor; IM = immune modulatory  
drugs; M = Melphalan; RT = Radiotherapy. 
PI/IM: 12  
M/IM: 1  
PI: 1  
PI/IM/RT: 5 
 
Prior Autologous/Allogeneic transplant AUTO: 13  
Both:  2 
NO transplant: 4  
 
ECOG                                                               O 
                                                                         1   
                                                                         2 
11 
7 
1 
 
DLTs in cycle 1 defined as: grade >3 non-hematological toxicities, grade >3 reactions  
at the site of injection, grade >3 hematological toxicities lasting > 7 days and/or requiring  
therapy, febrile neutropenia, aPTT ≥1.5 to 2.5 times the upper limit of normal (ULN) (≥Grade 
 2) and inability to retreatment or to receive at least 75% of study drug. 
*1 pt received one day of treatment for early PD, one additional patient (pt) enrolled, to get  
3 pts evaluable for DLTs. 
**1 additional pt had intra-patient dose escalation from 25 (2
nd
 cohort) to 50 mg (3
rd
 cohort)  
at cycle 4 and 5, approval granted by the local Ethical Committee. Although pt started in 2
nd
  
cohort, the protocol requirement of 3 different patients in the 3
rd
 cohort is met.  
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Table 2 
Unrelated and related AEs in the safety population, consisting of 19 patients; the number of patients per cohort is 
reported as (N). 
 
 
Schedule A Schedule B 
Patients presenting with at least one unrelated or related AE.  For each dose level it is reported the 
number of patients (n) and the percentage of patients (%), based on N, presenting an AE, and the 
number of events (E). 
 25 mg/day 
(N=4) 
n   (%)    E 
25 mg/day 
(N=3) 
n   (%)   E 
50 mg/day 
(N=2) 
n    (%)    E 
100 mg/day 
(N=3) 
n     (%)    E 
200 mg/day 
(N=3) 
n   (%)   E 
400 mg/day 
(N=4) 
n    (%)    E 
Patients with at least 
one RELATED OR 
UNRELATED AE  
(all causality) 
 
2    (50 )   7 
 
3  (100)  16 
 
2  (100)   19 
 
3   (100)    12 
 
3   (100)    20 
 
4   (100)   14 
 
Patients with at least 
one RELATED AE 
(type of AE) 
0              0 0            0 1   (50)   1 
(Viral 
infection) 
1   (33.3)  1 
(Injection site 
reaction) 
1    (33.3)  1 
(Upper 
abdominal 
pain) 
0               0 
Most common unrelated or related AEs reported in at least 10 % of patients: percentages based on 
N. A patient with multiple events within a Preferred Term (PT) is counted only once in the PT 
AE 
Preferred term (PT) 
25 mg/day 
(N=4) 
n (%) 
25 mg/day 
(N=3) 
n (%) 
50 mg/day 
(N=2) 
n (%) 
100 mg/day 
(N=3) 
n (%) 
200 mg/day 
(N=3) 
n (%) 
400 mg/day 
(N=4) 
n (%) 
Anemia 
0 1 (33.3) 0 1 (33.3) 2 (66.7) 0 
Thrombocytopenia 
1 (25.0) 0 0 0 0 2 (50.0) 
Upper abdominal 
pain  
0 1 (33.3) 0 0 1 (33.3) 0 
Diarrhoea 
0 0 1 (50.0) 0 0 1 (25.0) 
Nausea 
0 2 (66.7) 0 0 0 0 
Asthenia 
0 2 (66.7) 0 0 0 1 (25.0) 
Fatigue 
1 (25.0) 0 0 0 1 (33.3) 0 
General Physical 
Health Deterioration 
1 (25.0) 1 (33.3) 0 0 0 1 (25.0) 
Arthralgia 
0 0 1 (50.0) 0 1 (33.3) 0 
Back Pain 
0 1 (33.3) 1 (50.0) 1 (33.3) 1 (33.3) 0 
Bone Pain 
0 0 0 2 (66.7) 0 0 
Insomnia 
0 0 0 1 (33.3) 0 1 (25.0) 
Cough 
0 0 0 0 2 (66.7) 0 
Epistaxis 
1 (25.0) 0 0 1 (33.3) 0 1 (25.0) 
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Table 3 
Response rates in the efficacy population, consisting of 17 patients.  
 
 CR  VGPR PR MR SD  PD 
OVERALL RESPONSES  
(all cohorts) – n/17   (%)       
 
 
0/17 
 
0/17 
 
1/17  (5.9 %) 
 
0/17 
 
9/17  (52.9%) 
 
7/17 (41.2%) 
RESPONSES BY DOSING  
COHORTS – n/N (%) 
Schedule A  
              25 mg (N= 3) 
 
Schedule B  
              25 mg (N= 3) 
              50 mg (N= 2) 
            100 mg (N= 3) 
            200 mg (N= 3) 
            400 mg (N= 3) 
 
 
 
0/3 
 
 
0/3 
0/2 
0/3 
0/3 
0/3 
 
 
 
0/3 
 
 
0/3 
0/2 
0/3 
0/3 
0/3 
 
 
 
0/3 
 
 
0/3 
1/2 (50%) 
0/3 
0/3 
0/3 
 
 
 
0/3 
 
 
0/3 
0/2 
0/3 
0/3 
0/3 
 
 
 
0/3 
 
 
2/3 (66.7%) 
1/2 (50%) 
1/3 (33.3%) 
2/3 (66.7%) 
3/3 (100%) 
 
 
 
3/3 (100%) 
 
 
1/3 (33.3%) 
0/2 
2/3 (66.7%) 
1/3 (33.3%) 
0/3 
CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease 
n: number of responses;  N: number of patients evaluable for efficacy. 
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SUPPLEMENTUM 1 
 
Roneparstat did show a very good activity when combined with dexamethasone.1 Roneparstat (60 
mg/kg/day for 14 days) and dexamethasone (1 mg/kg/day for 14 days) combination therapy was 
tested against subcutaneous Myeloma tumor growth in SCID mice (using human MM.1R Myeloma 
cells) and in Balb/c mice (using murine MPC-11 Myeloma cells), thereby representing drug-resistant 
and immuno-competent models of Myeloma, respectively. In both settings, the combination therapy 
significantly inhibited tumor growth more effectively than single agent therapy alone. In the drug-
resistant MM.1R model, combination therapy inhibited tumor growth by 80% and in the syngeneic 
model, combination therapy inhibited tumor growth by 97%. In both cases, assessment of the 
combination of Roneparstat and dexamethasone revealed a synergistic effect in inhibiting Myeloma 
tumor growth (Table S1). 
 
Table S1 - Roneparstat in combination, preclinical models.  
Model Dose  Results 
TVI % κ chains 
% inhibition 
MM.1R model, tumour 
cells injected sc 1 
 
SCID mice 
60 mg/kg/day   
sc injection + 
dexamethasone 1 
mg/kg/day  
80 - 
Syngeneic (MPC-11) model 
cells injected sc 1 
 
Balb/c mice 
60 mg/kg/day   
sc injection + 
dexamethasone 1 
mg/kg/day  
97 - 
CAG HPSE high cells model 
Cells intravenously injected 
in mouse tail veins 2 
 
SCID mice 
120 mg/kg/day   
sc injection + 
bortezomib 0.5  
mg/kg/twice a week  
75%-80% 
(Tumour burden 
reduction by 
bioluminescence 
assay) 
70 
(only 3/10 animals 
had detectable levels 
of serum κ) 
CAG HPSE high cells model 
Cells intravenously injected 
in mouse tail veins 2 
 
SCID mice 
60 mg/kg/day   
sc injection + melphalan 
1  mg/kg/week  
90%-95% 
(Tumour burden 
reduction by 
bioluminescence 
assay) 
100 
 
TVI: tumour volume inhibition; k: human kappa light chain; SCID: Severe Combined 
Immunodeficiency; sc: subcutaneous 
 
 
 
 
2 
 
 
A preclinical in vivo combination experiment evaluated CAG human Myeloma cells expressing high 
levels of HPSE (CAG HPSE cells), intravenously injected in mouse tail veins.2 The CAG HPSE cells are 
very aggressive, they home to and grow rapidly and almost exclusively in the mouse bones (21 days 
post-injection), as evidenced by bioluminescence signal, mimicking the late stages of Myeloma. Tumor 
burden was evaluated by measurement of kappa-levels and bioluminescence after combination 
treatment with Roneparstat (120 mg/kg/day for 14 days) plus bortezomib (0.5 mg/kg/twice a week 
for 14 days) (Table S1) or Roneparstat (60 mg/kg/day for 14 days) plus melphalan (1 mg/kg/week for 
14 days) (Table S1). Results showed that bortezomib and melphalan efficacy in tumour inhibition was 
substantially increased when they were combined with Roneparstat. This was evident both from 
kappa-levels and bioluminescence imaging data; a decrease in the former was always paralleled by a 
decrease of the latter. This increased efficacy was shown also when Roneparstat was given as 
sequential therapy after Melphalan.2  
Positive data of Roneparstat efficacy when combined with Bortezomib or Melphalan are supported 
by the fact that chemotherapies are known to increase HPSE expression.3  
Roneparstat also showed activity in tumors other than Myeloma. In particular, an antitumor effect 
was reported in lymphomas when given alone (60 mg/kd/day) or in combination with 
Cyclophosphamide, Rituximab or Bevacizumab.4 Similarly, a strong inhibitory effect was reported in 
sarcomas models at 60mg/kg/twice daily, especially when combined with 50 mg/kg/day Irinotecan.5 
 
Supplementary Figure S1 reports the plasma profiles of individual patients receiving 200 mg and 400 
mg. Plasma levels of Roneparstat were quantifiable at cycle 1 at the two highest dose levels after 
single (day 1) and repeated (day 12) dosing using fluorescent probe assay (Heparin Red).6  
Systemic exposure appears reproducible, linear but slightly over-proportional with the dose. These 
data seem to reflect preclinical PK (rat & monkey).7 
With all the caution due to the translation from preclinical to clinical findings, the reported plasma 
levels are coherent with preclinical data showing that the inhibitory ability of the drug is in the 
nanomolar range, with an IC50 value corresponding to 0,06 µg/mL.8 Moreover, a non-clinically 
significant increase of aPTT and of TT was detected in one and two patients receiving 400 mg, 
respectively, thus further showing patient exposure to the drug. 
The effect on coagulation occurring in the patients who received 400 mg suggested this as the highest 
dose level to be explored. In combination phase I/II studies the dose identified to be used will be 300-
400 mg/day. 
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Figure S1 - Day 1 and Day 12 plasma profiles in patients treated with Roneparstat 200 mg (3 patients) 
and 400 mg (3 patients). 
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